Table 4.

Univariate analysis for cGvHD

Characteristics	HR (95% CI)	P value
Age(15–40 vs > 40years)	0.486 (0.169–1.395)	0.180
Gender (male vs female)	0.57 (0.2–1.623)	0.293
Risk classification at diagnosis (intermediate risk vs high risk)	0.384 (0.132–1.116)	0.079
HLA matched (10/10 matched vs 9/10 matched)	1.316 (0.394–4.393)	0.655
Median interval from diagnosis to HSCT (< 12 vs ≥ 12 months)	0.608 (0.176–2.109)	0.433
BM blasts at transplantation (< 20 vs ≥ 20%)	0.249 (0.061–1.017)	0.053
Initiate time of tapering of immunosuppressive agents (early vs routine)	5.182 (1.669–16.085)	0.004
Conditioning regimen (BFCT vs BCAT)	0.971 (0.344–2.742)	0.956
aGvHD of grades II–IV (with vs without)	3.076 (1.013–9.338)	0.047
CMV viremia (without vs with)	0.684 (0.241–1.942)	0.476